Norwegian-based Telenor ASA,  the primary shareholder in GrameenPhone in Bangladesh with operations in Pakistan, Malaysia and Thailand, bought a 60% stake in India’s Unitech Wireless at the end of 2008. The deal is expected to be finalized in Q1 of 2009.

Analysts were initally quite critical of the deal, as Unitech has no network to speak of, and Telenor’s stock dipped on the announcement.  However, Unitech Wireless holds licenses for all 22 mobile regions of India–the world’s 2nd biggest market after China–which would appear to be a valuable asset even in a very competitive market. Consider that a few years ago, Telenor spent $1.9 billion to buy a license in Serbia! Coupled with Telenor’s experience and success in South and Southeast Asia, an Indian play of this magnitude makes long-term strategic sense.

Telenor says the deal is contingent on sharing infrastructure, perhaps eyeing the 30,000-50,000 cell towers of its entrenched competitors. While unstated, Telenor is likely looking to the new company Indus Towers, started by Bharti, Vodafone Essar, and Idea Cellular,  to share network assets.

Since the announcement, Telenor has indicated it will not pay shareholder dividends in 2008 or 2009, and will take out a three-year loan to pay for its investment. Telenor’s share price, which lost 64% of its value in 2008, has recovered somewhat in early 2009 trading.

GrameenPhone, the primary case study in You Can Hear Me Now, is preparing to sell $300 million worth of shares on the Dhaka and Chittagong stock exchanges in Bangladesh. The company, a subsidiary of Norway’s Telenor, is valued at $3.2 billion. Get more details from The Daily Star, Dhaka’s premier English-language daily.

The IPO, although very small by Western standards, is a significant step forward for Bangladesh’s capital markets, which have been strengthening over the part five years. “It will be a breakthrough for the country’s capital market history,” said Abu Ahmed, professor of the Department of Economics of Dhaka University. The IPO is planned for the end of September.

The fact that GrameenPhone, which is owned by Telenor, a publicly traded company in Norway, is offering shares in Bangladesh is significant because it gives Bangladeshis a chance to buy into one of the country’s strongest corporate performers. This has long been a bone of contention between Muhammad Yunus, the Nobel laureate and founder of Grameen Bank, which owns 38% of GrameenPhone, and Telenor, which owns 62%. At his Nobel acceptance in Oslo, Yunus made several “in your face” comments about Telenor. Yunus now asserts that the owners of Grameen Bank are entitled to buy 20% of the shares being offered and that they have the capital to do so.

This silly jousting aside, the IPO may well propel other telecoms to list in Bangladesh, including Egypt’s hyper-successful Orascom, which operates Banglalink.

That cellphones are full-fledged computers useful for a lot more than basic communications is well known, but actual, practical applications are just coming online. To date, most have been in the transfer of market information (CellBazaar) and money (M-PESA), with a host of trials in the medical arena. But getting doctors to use new technology isn’t always easy–unless it fits right into what they are used to doing.

ClickDiagnostics, a new company spawned at MIT (and winner of the MIT Enterprise Forum’s $100K competition in the “development” field), may have accomplished that. The idea is to use cell phones in the field, particularly remote rural areas, to take pictures of people’s eyes and skin, then transmit those images to doctors for diagnosis of cataracts and skin cancer. In an initial test last winter students travelled to Bangladesh to shoot images, then tested their quality with doctors at Massachusetts General Hospital (aka MGH, aka “man’s greatest hospital”) in Boston. The doctors said they were of high enough quality to make an initial diagnosis and prescribe a treatment regimen–or point to the need for immediate hospital-related care.

In addition to the common skin disease prevalent in all developing countries, these simple cell phone images can detect the onset of HIV, Malaria, Hepatitis C, and TB. To the extent the product can be deployed in the field, it could have a huge impact on the early recognition and treatment of these debilitating and potentially deadly diseases.

With the MIT prize and some seed funding under its belt, ClickDiagnostics has its first contract to provide service in Egpyt, starting this fall.

CellBazaar, a kind of “Craig’s list for cell phones” that is available only on GrameenPhone in Bangladesh, won the Best Use of Mobile for Social and Economic Development Award at the GSM Association’s blowout meeting in Barcelona, Spain. Here’s the citation:

“Grameenphone CellBazaar is a user-generated virtual marketplace, accessible via mobile phone or PC to nearly 17 million people in Bangladesh. In developing countries, limited communications hinder commerce and uninformed farmers and traders have little bargaining power with exploitative middlemen. Using CellBazaar, buyers and sellers trade basic goods from their mobiles, bringing the benefits of information exchange and one-to-many trading to a previously unwired rural population. Users post or search an item, spending less than US$.02, either by SMS or WAP or WEB, depending on their preferences. While common telephony establishes one-to-one communication, CellBazaar links many-to-many using the same basic mobile infrastructures.”

Judges’ comments: “Great initiative – full marks for self-sustainability. This grass root level initiative is not only for operators to make money but for rural folks to sell and trade their goods and increased price transparency and help for the illiterate is also available. It has clear environmental benefits through reduced travel.”

CellBazaar was founded by Kamal Quadir, brother of Iqbal Quadir, one of the founders of GrameenPhone. The company was initially developed by Quadir when he was a student at MIT’s Sloan School of Management, and was a prize winner at MIT’s annual $100K Entrepreneurship Competition.

See the proud press release on Telenor’s web site.

Here’s a report I submitted to the Development Through Enterprise blog at www.nextbillion.net:

“The 8th annual Harvard Social Enterprise Conference last Sunday (March 6) at the Harvard Business School drew a sellout crowd of 1,000 people. Cheryl Dorsey, president of Echoing Green, and Victoria Hale, founder and ceo of the Institute for One World Health, gave morning keynotes.

Echoing Green acts as an “angel for emerging social enterprises,” and has awarded $25 million to more than 400 entrepreneurs since 1987. Dorsey noted that when she graduated from medical school, she intended to practice medicine, but saw a Boston Globe story on the high incidence of infant mortality in Boston’s black neighborhoods. It was this “ZIP code as destiny” epiphany that led her in 1992 to start The Family Van, a community-based mobile-health unit that provides basic medical services to at-risk residents in Boston’s inner city neighborhoods, and earned her an Echoing Green fellowship.

Dr. Hale is an Ashoka Fellow festooned with awards from The Economist, Skoll Foundation, and Schwab Foundation, not to mention a MacArthur Fellowship. She is founder of the America’s first non-profit pharmaceutical company, which recently received Indian government approval (FDA approval in 2005) for a low-cost drug to combat Visceral Leishmaniasis, a deadly disease of the spleen and liver that occurs primarily in the Indian state of Bihar (as well as Nepal and Bangladesh). More “geography as destiny,” for in this state alone a sand fly bite injects the deadly parasite. She showed slides of children with inflated bellies trying to fight off infection, slides of Indian women and girls with red hair due to malnutrition. Because the disease is confined to a poor and remote region, it has not been on the radar screen for big pharma, but Hale has corralled industry to develop a low cost drug.

One World Health now has a $10, 21-day cure, but still has to deal with the issue of distribution and education. Hale notes that of all the big pharma companies who have tried to develop effective drugs to combat diseases in poor countries (Glaxo Smith Kline, Merck, Pfizer, Novartis, Eli Lilly), only Merck has succeeded—with its cure for river blindness in Africa. Hale is out to change that lamentable track record, and noted that “industry doesn’t know the world’s poorest people, doesn’t know what need doing, but they want to do well and do good. We need to ask, she says, ‘What do you need to engage? What are you afraid of?’”

The “Private Capital in Development” panel, moderated by HBS’s Michael Chu, former CEO of ACCION International, was superb. Sarah Alexander, executive director of EMPEA (Emerging Markets Private Equity Association), noted that $33 billion in private equity flowed into emerging markets in 2006, compared to $26 billion in 2005, $6.4 billion in 2004, and $3.5 billion in 2003. She also noted that the “barbarians at the gate” (Carlyle and Blackstone?) mentality was widespread in Europe and emerging markets, and that private equity’s image in developing countries was an issue for governments. They want the money; they don’t want the buyouts, the cut-and-run.

Yasminda Zaidman, a director at Acumen Fund a non-profit venture capital fund (one of my favorite oxymorons), says they use “philanthropic capital to show private capital the path.” She also mentioned the “lost year” that many social entrepreneurs face when they try to start a business and spin regulatory and financing wheels for 365 days. Acumen prefers loans to equity, as “it’s hard to see exits.” Milton Namude of the IFC split the difference, saying the IFC took a long-term horizon, using debt and equity when needed, that private equity and venture capital were a small piece of the puzzle. He urged students to “join the IFC and have it all!”

The “Past, Present and Future of Microfinance” panel, also moderated by Michael Chu, hit the many fissures in the microfinance industry. Nancy Barry, president of Women’s World Banking, started out by saying that Grameen Bank was a huge success but had not innovated on its original models, and that MFIs should not be “loan dispensers” but “financial intermediaries” that provided insurance, savings, and consumer finance. Jeffrey Ashe, manager of community finance for Oxfam America, noted that 6 of 7 borrowers come from a “handful of countries” and that his Saving for Change Initiative aims to promote savings (rather than lending) as a way of changing lives and mobilizing capital. Carlos Castello of ACCION International, spoke about the commercialization of microfinance. Of ACCION’s 33 partners, 28 are generating better than 20% returns. He pressed the idea that returns were key to sustainable success.

All panelists talked about the impact of commercialization, and saw a split in the industry between banks that moved further upstream (targeting the rich poor), and NGOs that moved further downstream (targeting the poor poor).

This conference moved the ball, however defined, forward.”

http://www.nextbillion.net

GrameenPhone was presented with the GSM Association’s Global Mobile Award for “Best use of mobile for social and economic development” for its HealthLine telemedicine service. The award was presented to CEO Erik Aas during the GSM Association’s Annual Leadership Summit in Barcelona.

In acccepting the award, Erik Aas said:

GrameenPhone and the mobile industry represent a major part of the development of Bangladesh, and this initiative shows our commitment to the development of the country, the people and their well-being.”

The HealthLine service is an interactive teleconference between a GP caller and a licensed physician who will dispense information on lab tests and lab reports, drugs, and medical facilities.

Muhammad Yunus, founder of Grameen Bank and winner of the 2006 Nobel Peace Prize, is almost certain to enter politics within the month and step down from Grameen Bank, according the Dhaka’s Daily Star. He is expecting to run as an independent in Bangladesh’s upcoming elections. An editorial in the Daily Star, “We need local leaders not national personalities,” written by an ex-pat Bengali, takes a dim view of this prospect. Ironically, others within Bangladesh feel that Yunus more appeal more to Westerners and ex-pats than those living in the country. But, no one knows, least of all Yunus himself.

Asked what he would be like in a partisan role, he replied, “I do not know.”

Separately, Yunus this week announced he wants GrameenPhone to list on the Dhaka Stock Exchange and offer one share to each of Grameen Bank’s 6.9 million borrowers.

Grameenphone Ltd. of Bangladesh has been nominated for the GSMA Best Use of Mobile for Social and Economic Development award 2007 for its HealthLine Service initiative. The HealthLine Service, implemented in cooperation with the Telemedicine Reference Center Limited, is a 24-hour Medical Call Center manned by licensed physicians and can be reached by dialing 789 from any GP number.

Doctors are on hand 24 x 7 to answer questions on medical emergencies, faciliites, drugs, and lab tests. Registered users can speak directly with a doctor about their specific condition. In a country where hospitals are few and far between, and travel is often difficult and time-consuming, this is a huge social benefit.

Registration costs Tk300 per year (about $5), and calls cost Tk15 for 3 minutes, Tk5 for every minute thereafter. (Tk60=$1.)

I discussed a fledgling telemedicine program with GrameenPhone chairman Khalid Shams while researching the book, but didn’t mention it because the program was not taking hold. It just shows you how quickly things are changing — six months later, the nascent program is well-enough developed to catch the eyes of the global GSM Association.

In 2000, GrameenPhone won the GSM in the Community award for its village-phone service, which extends telecommunications into remote rural areas. Village-phone ladies borrown money from Grameen Bank to buy phones, then lease time to villagers to pay back the loans.

The award winner will be announced at the GSMA conference in Barcelona in mid February.

A very interesting opinion piece in the Jan. 29 Wall Street Journal notes that both the Nobel Prize winner in economics (Edmund Phelps) and peace (Muhammad Yunus) highlighted the impact of entrepreneurship in their Nobel addresses. “Phelp’s Prize” by Amar Bhide, a professor at Columbia University, and Carl Schramm, president of the Kauffman Foundation, picks at the open wound between plain-old entrepreneuers and social entrepreneurs. I basically agree with them, but I also beg to differ as I think they compare apples and oranges. (I don’t link to the article because I don’t have a subscription to wsj.com.)

Of the 35 winners in economics, 28 never mentioned the word “entrepreneur.” Phelps mentioned it 17 times–more than the total over the previous 19 years! Yunus mentions it 6 times. Twenty-three mentions in two Nobel speeches has to be a record. But it is almost as if the laureates had a different dictionary in front of them when choosing their words.

Phelps talks about a transformative entrepreneurship that is central to capitalism, by sparking growth of small businesses that become large commercial operations; Yunus talks about microloans that don’t involve economies of scale or lead to significant new enterprises. The writers ask, ” Can turning more beggars into basket weavers make Bangladesh less of a, well, basket case?”

Well, no–but. It’s a false dichotomy–and the writers know it. They note Bangladesh’s export-oriented garment industry as being “larger and more productive than individual craftsman,” which is true, as a way of saying that it is better to provide venture capital to growing businesses than seed capital to individuals. They also note that government reforms, such as those that are now propelling Vietnam to new heights, are more important than microloans. But because the Bangladesh government is intractably backward and corrupt and anti-private business, does that mean that Yunus’s loans are a bad thing? I think the writers are reacting to the hoopla rather than the reality.

I am not an unabashed proponent of microloans, because I agree with the writers that while they may lift individual families out of poverty, they do not scale an economy. But I do not think microloans are a bad thing–how could they be? Some, such as Alexander Cockburn in The Nation (“The Myth of Microloans”), paint microloans as the devil incarnate, due to farmer suicides in India.

To me, the issue is clear: Capital that helps people raise a cow and escape poverty is as good as capital that helps start an Apple Computer. Yes, there’s a difference of scale. But there’s also a difference of context. The two sources of capital are not comparable–one’s in America, one’s in Bangladesh. But that doesn’t mean they’re not both productive.

And what about microloans that help build a GrameenPhone, the largest and most successful business in Bangladesh? It would not have been built without microloans that allowed distribution into rural villages, because Grameen Bank would not have backed the project. Does that not count? The authors cannot take a potshot at Yunus’s track record without examining his full portfolio.Â

Straw-man arguments are not compelling. It’s not either-or. Let’s deal with the facts on the ground–and celebrate entrepreneurs and capital that builds businesses of all kinds.

The Anwarul Quadir prize of $25,000, administered by the Center for International Development at Harvard’s Kennedy School, is open to anyone and any idea in the world. The prize will be awarded for the essay that points to the most innovative approach for improving the social and economic development of low- and middle-income people in Bangladesh. The essay must show how the idea will be put into practice, garner support, and who or what type of institution (government, private business, NGO, etc.) will carry it out. Essays must by received by June 30, 2007. For more information, see the contest website at Harvard’s Center for International Development.

Essays will be judged by four Harvard professors (two men, two women) and the winner will be selected in October 2007. The prize will be awarded in January 2008 in Dhaka, Bangladesh, at a conference heralding innovation–past, present and future– in Bangladesh.